ARS Pharmaceuticals reported earnings of -$ 0.36 per SPRY share on Nov 5, 2026, beating analysts' expectations by
| Report Date | Nov 5, 2026 |
|---|---|
| Forecasted EPS | -$ 0.31 |
| Earnings Per Share (Surprise) | -$ 0.36 (-$ 0.05) |
| Last Year's EPS | -$ 0.44 |
| EPS YoY Change |
Out of the last 27 earnings reporting periods, ARS Pharmaceuticals beat analysts’ expectations 7 times and fell short of expectations 14 time(s). ARS Pharmaceuticals reported earnings per share of -$ 0.36 in the last report falling to reach an estimated EPS of -$ 0.31 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 5, 2026 | -$ 0.31 | -$ 0.36 | -$ 0.52 | |
| Aug 13, 2026 | -$ 0.48 | -$ 0.63 | -$ 0.46 | |
| May 15, 2026 | -$ 0.53 | -$ 0.61 | -$ 0.35 | |
| Mar 9, 2026 | -$ 0.42 | -$ 0.42 | $ 0.52 | |
| Nov 10, 2025 | -$ 0.45 | -$ 0.52 | -$ 0.20 | |
| Aug 13, 2025 | -$ 0.41 | -$ 0.46 | -$ 0.13 | |
| May 14, 2025 | -$ 0.35 | -$ 0.35 | -$ 0.11 | |
| Mar 20, 2025 | -$ 0.04 | $ 0.52 | -$ 0.07 | |
| Nov 13, 2024 | -$ 0.18 | -$ 0.20 | -$ 0.16 | |
| Aug 6, 2024 | -$ 0.12 | -$ 0.13 | -$ 0.18 | |
| May 9, 2024 | -$ 0.11 | -$ 0.11 | -$ 0.16 | |
| Mar 21, 2024 | -$ 0.14 | -$ 0.07 | $ 0.77 | |
| Nov 9, 2023 | -$ 0.18 | -$ 0.16 | -$ 0.50 | |
| Aug 10, 2023 | -$ 0.17 | -$ 0.18 | -$ 0.55 | |
| May 15, 2023 | -$ 0.17 | -$ 0.16 | -$ 0.70 | |
| Mar 23, 2023 | -$ 0.13 | $ 0.77 | -$ 0.67 | |
| Nov 2, 2022 | -$ 0.35 | -$ 0.50 | -$ 0.65 | |
| Aug 11, 2022 | -$ 0.48 | -$ 0.55 | -$ 0.70 | |
| May 12, 2022 | -$ 0.54 | -$ 0.70 | -$ 0.54 | |
| Mar 31, 2022 | -$ 0.70 | -$ 0.67 | -$ 1.37 |
ARS Pharmaceuticals’s stock was trading at $ 3.05 on Nov 4, 2026 a day before the last earnings report was released.Following the release of the earnings report, SPRY’s price decreased to $ 2.79 on Nov 6, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 5, 2026 | -$ 0.36 | $ 3.05 | $ 2.79 | |
| Aug 13, 2026 | -$ 0.63 | $ 6.05 | $ 5.65 | |
| May 15, 2026 | -$ 0.61 | $ 7.94 | $ 7.30 | |
| Mar 9, 2026 | -$ 0.42 | $ 9.06 | $ 8.86 | |
| Nov 10, 2025 | -$ 0.52 | $ 8.85 | $ 8.77 | |
| Aug 13, 2025 | -$ 0.46 | $ 16.66 | $ 14.47 | |
| May 14, 2025 | -$ 0.35 | $ 13.35 | $ 12.20 | |
| Mar 20, 2025 | $ 0.52 | $ 11.65 | $ 12.36 | |
| Nov 13, 2024 | -$ 0.20 | $ 16.61 | $ 14.11 | |
| Aug 6, 2024 | -$ 0.13 | $ 9.32 | $ 9.57 | |
| May 9, 2024 | -$ 0.11 | $ 9.06 | $ 8.74 | |
| Mar 21, 2024 | -$ 0.07 | $ 8.70 | $ 8.65 | |
| Nov 9, 2023 | -$ 0.16 | $ 3.58 | $ 3.73 | |
| Aug 10, 2023 | -$ 0.18 | $ 6.89 | $ 6.83 | |
| May 15, 2023 | -$ 0.16 | $ 8.04 | $ 8.17 | |
| Mar 23, 2023 | $ 0.77 | $ 7.99 | $ 7.59 | |
| Nov 2, 2022 | -$ 0.50 | $ 6.15 | $ 6.06 | |
| Aug 11, 2022 | -$ 0.55 | $ 5.03 | $ 5.08 | |
| May 12, 2022 | -$ 0.70 | $ 2.90 | $ 2.96 | |
| Mar 31, 2022 | -$ 0.67 | $ 3.52 | $ 3.21 |
ARS Pharmaceuticals released its most recent earnings reports in November 2026, August 2026, May 2026, March 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
ARS Pharmaceuticals missed analysts’ expectations during the last earnings period by
